| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 439.71 | 14.5% | 10.5% |
| Total Income | 447.76 | 13.2% | 11.4% |
| Expenditure | 393.29 | 1.7% | 19.2% |
| PBT | 54.48 | 57.9% | 57.4% |
| Net Profit | 40.57 | 58.1% | 60.1% |
| OPM | 17.54% | 12.71pp | 8.93pp |
| NPM | 9.06% | 9.71pp | 16.21pp |
| EPS | 31.62 | 58.1% | 60.1% |
Neuland Laboratories Reports Q3FY26 Total Income at Rs.1264.5 crore, EBITDA at Rs.284 crore
09 Feb 2026 · 9 Feb, 4:22 pm
Summary
Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the quarter and nine months ended December 31, 2025. The company reported a total income of Rs.1264.5 crore and EBITDA of Rs.284 crore. The revenues are in line with the outlook, but the product mix and increased operating expenses have affected the EBITDA margins.
Key Highlights
- 1
Q3FY26 Total Income: Rs.1264.5 crore
- 2
Q3FY26 EBITDA: Rs.284 crore
- 3
YoY growth in Q3FY26 EBITDA: -5.9%
- 4
QoQ growth in Q3FY26 EBITDA: -45.8%
- 5
Q3FY26 EBITDA Margin: 19.0%
- 6
Q3FY26 PBT Margin: 12.1%
- 7
Q3FY26 Profit After Tax: 40.4 crore
- 8
Increasing interest from a wider range of customers
- 9
Investments leading to more engagements with existing customers and attracting new customers
Management Comments
Mr. Sucheth Davuluri
Vice-Chairman and Chief Executive Officer
The revenues this quarter are in line with the outlook we envisaged for the year, however the product mix within businesses as well as increased operating expenses is reflected in subdued EBITDA margins. We continue to see good momentum in the business which is driving our investments with the long-term in view, ensuring Neuland can take advantage of the number of growth opportunities.
Mr. Saharsh Davuluri
Vice Chairman and Managing Director
We are seeing increasing interest from a wider range of customers interested in our capabilities as a proven commercial NCE drug substance manufacturer as well as an integral partner in the innovation journey. Our investments are leading to more engagements with existing customers while also attracting new customers who are looking for specific niche capabilities.
Informational and educational content only. Not investment advice.